TULIP · Untapping the potential for improved female reproductive healthcare: diagnosing and reinforcing the status of UTERINE-associated fertility
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-01-01 → 2029-12-31
- Финансиране от ЕС
- 1 803 600 €
- Участници
- 12
- Схема
- HORIZON-TMA-MSCA-SE
Линиите свързват координатора с партньорите.
Накратко на български
Връзката между микробиома и захарите в матката определя възможността за успешно зачеване и развитие на плода. По-доброто разбиране на тези процеси помага за създаването на по-точни диагностични методи и персонализирано приложение на асистираната репродукция.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Conception and pregnancy are both complex processes, with approximately 1 in 6 women worldwide experiencing infertility, often due to compromised uterine function, the organ designed solely for sustaining life. However, these dysfunctional uterine mechanisms remain not fully understood. Moreover, assisted reproduction technologies (ART) are employed to address infertility, with 5% of newborns in Europe conceived through ART. Nevertheless, the use of ART still results in low pregnancy success rates, with uterine dysfunction being a significant factor. This underscores the importance of the uterus in medical research, which has previously received little attention for its pivotal role in the journey towards motherhood.The TULIP consortium focuses on emerging topics, including the interplay between glycosylation and the microbiota within the uterus in relation to fertility. This interdisciplinary consortium comprises experts from six European countries, representing eight academic and four industry partners, and uniquely combines specialists in female reproductive medicine with researchers in glycobiology, microbiota studies, genomics, and data science. We aim to achieve a breakthrough in understanding the core biological aspects of conception, thereby fostering accurate and less invasive diagnostic methods that lead to more effective and personalised implementation of ART through pioneering tools designed to overcome poor reproductive outcomes.This breakthrough will be achieved by engaging 33 early-stage researchers in a collaborative interdisciplinary training and research programme. The programme seeks to emphasise scientific knowledge while fostering entrepreneurial and transferable skills over the 48-month project period. Collectively, these efforts enhance diagnostic and therapeutic tools to improve reproductive success in both natural and assisted conception while reinforcing inter-sectoral and interdisciplinary collaborative networks and the R&I capacity.
Оригинален текст от CORDIS (на английски).
Участници
- KAROLINSKA INSTITUTET · STOCKHOLMКоординаторШвеция
- CELVIA CC AS · TartuЕстония
- FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA · ValenciaИспания
- INSTITUTO AVANTIA DE FERTILIDAD SL · GRANADAИспания
- IVI VALENCIA SL · VALENCIAИспания
- NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED · BLACKROCK DUBLINИрландия
- NATIONAL UNIVERSITY OF IRELAND MAYNOOTH · MaynoothИрландия
- PANEPISTIMIO KRITIS · RETHIMNOГърция
- TARTU ULIKOOL · TartuЕстония
- UNIVERSIDAD DE GRANADA · GranadaИспания
- UNIVERSITAIR MEDISCH CENTRUM UTRECHT · UtrechtНидерландия
- UNIVERSITEIT MAASTRICHT · MaastrichtНидерландия
Връзки
Данни: CORDIS, © Европейски съюз
